Trial Profile

A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Plaque Psoriasis in Adults

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Apr 2025 According to a Dermavant Sciences media release, Based on results from two pivotal trials ie.PSOARING 1 and PSOARING 2, Health Canada has approved NDUVRA (tapinarof cream), 1%, the first in a novel class of aryl hydrocarbon receptor agonists to be approved in Canada, for the topical treatment of plaque psoriasis in adults.
25 Jun 2024 According to a Dermavant Sciences media release, company announced that Japan Tobacco has received approval in Japan for tapinarof cream, 1% for the treatment of adults with psoriasis.
12 Dec 2023 Results from PSOARING 1 and PSOARING 2 , assessing patient-reported pruritus outcomes, published in the Dermatology and Therapy

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com